Ibrutinib/venetoclax shows early promise in relapsed CLLJuly 11, 2018Lymphoma & Plasma Cell Disorders
PET-driven chemo strategy helps reduce toxicity in Hodgkin lymphomaJuly 6, 2018Lymphoma & Plasma Cell Disorders
Daratumumab plus carfilzomib/dexamethasone effective in lenalidomide-refractory myelomaJuly 2, 2018Lymphoma & Plasma Cell Disorders
CAR T in DLBCL: Liso-cel has ‘remarkable’ efficacy in cohortJune 27, 2018Lymphoma & Plasma Cell Disorders
Combo treatment under review for Waldenstrom macroglobulinemiaJune 26, 2018Lymphoma & Plasma Cell Disorders
DLBCL survival improved with novel antibody-drug conjugateJune 17, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA approves pembrolizumab for relapsed/refractory PMBCLJune 14, 2018Lymphoma & Plasma Cell Disorders
FDA grants regular approval to venetoclax for CLL/SLLJune 8, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLLJune 8, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Chemo-free regimen appears viable in previously untreated FLJune 7, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHLJune 6, 2018Immuno-oncologyLymphoma & Plasma Cell DisordersFollicular Lymphoma
